Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others

 Breaking News
  • No posts were found

Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others

December 05
20:24 2023
Exosomes Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group and others

DelveInsight’s, “Exosomes Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Exosomes Pipeline Report

  • DelveInsight’s Exosomes pipeline report depicts a robust space with 60+ active players working to develop 110+ pipeline therapies for Exosomes treatment.
  • The leading companies working in the Exosomes Market include Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
  • Promising Exosomes Pipeline Therapies in the various stages of development include Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.
  • December 2023: Direct Biologics LLC announced a study of Phase 3 clinical trials for ExoFlo. To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
  • November 2023: Organicell Regenerative Medicine announced a study of Phase 1 & 2 clinical trials for Zofin. The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
  • October 2023: Vitti Labs LLC announced a study of Phase 1 clinical trials for EV-Pure™. The VL-POI-01 study is designed to evaluate the safety and efficacy of human placental mesenchymal stem cell derived exosome treatment in patients with premature ovarian insufficiency (POI) and diminished ovarian reserve.

 

Request a sample and discover the recent advances in Exosomes Treatment Drugs @ Exosomes Pipeline Outlook Report

 

In the Exosomes pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Exosomes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Exosomes Overview

An exosome is a type of extracellular vesicle (EV), a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages released by most cells. Exosomes are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes.

 

Find out more about Exosomes Treatment Landscape @ Drugs for Exosomes Treatment

 

Exosomes Emerging Drugs Profile

  • CAP-1002: Capricor
  • Progenza: Regeneus
  • AGLE 102: Aegle Therapeutics
  • Zofin: Organicell Regenerative Medicine
  • Exo-101: Exogenus Therapeutics
  • COYA 201: Coya Therapeutics

 

Exosomes Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Exosomes. The Exosomes Companies which have their Exosomes drug candidates in the most advanced stage, i.e. phase III include, Capricor.

 

DelveInsight’s Exosomes pipeline report covers around 110+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Exosomes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Exosomes Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Exosomes Pipeline Therapies @ Exosomes Clinical Trials Assessment

 

Scope of the Exosomes Pipeline Report

  • Coverage- Global
  • Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Exosomes Companies- Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
  • Exosomes Pipeline Therapies- Exosome ointment, EV-Pure™, Zofin, Olmutinib, and others.

 

Dive deep into rich insights for new drugs for Exosomes Treatment, Visit @ Exosomes Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Exosomes: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Exosomes– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. CAP-1002: Capricor
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Progenza: Regeneus
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. StemXO Endosome Therapy: Stem XO Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Exo-101: Exogenus Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Exosome – Collaborations Assessment- Licensing / Partnering / Funding
  21. Exosomes- Unmet Needs
  22. Exosomes- Market Drivers and Barriers
  23. Appendix

 

For further information on the Exosomes pipeline therapeutics, reach out @ Exosomes Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Related Articles

Categories